Browse PTPN6

Summary
SymbolPTPN6
Nameprotein tyrosine phosphatase, non-receptor type 6
Aliases HCPH; PTP-1C; SHP-1; HPTP1C; SH-PTP1; SHP-1L; hematopoietic cell phosphatase; hematopoietic cell protein-tyr ......
Chromosomal Location12p13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm. Nucleus. Note=In neurons, translocates into the nucleus after treatment with angiotensin II (By similarity). Shuttles between the cytoplasm and nucleus via its association with PDPK1.
Domain PF00017 SH2 domain
PF00102 Protein-tyrosine phosphatase
Function

Modulates signaling by tyrosine phosphorylated cell surface receptors such as KIT and the EGF receptor/EGFR. The SH2 regions may interact with other cellular components to modulate its own phosphatase activity against interacting substrates. Together with MTUS1, induces UBE2V2 expression upon angiotensin II stimulation. Plays a key role in hematopoiesis.

> Gene Ontology
 
Biological Process GO:0000082 G1/S transition of mitotic cell cycle
GO:0001501 skeletal system development
GO:0001906 cell killing
GO:0001909 leukocyte mediated cytotoxicity
GO:0001933 negative regulation of protein phosphorylation
GO:0001959 regulation of cytokine-mediated signaling pathway
GO:0002228 natural killer cell mediated immunity
GO:0002244 hematopoietic progenitor cell differentiation
GO:0002250 adaptive immune response
GO:0002429 immune response-activating cell surface receptor signaling pathway
GO:0002443 leukocyte mediated immunity
GO:0002449 lymphocyte mediated immunity
GO:0002455 humoral immune response mediated by circulating immunoglobulin
GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002521 leukocyte differentiation
GO:0002683 negative regulation of immune system process
GO:0002694 regulation of leukocyte activation
GO:0002695 negative regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0002697 regulation of immune effector process
GO:0002698 negative regulation of immune effector process
GO:0002703 regulation of leukocyte mediated immunity
GO:0002704 negative regulation of leukocyte mediated immunity
GO:0002706 regulation of lymphocyte mediated immunity
GO:0002707 negative regulation of lymphocyte mediated immunity
GO:0002712 regulation of B cell mediated immunity
GO:0002713 negative regulation of B cell mediated immunity
GO:0002757 immune response-activating signal transduction
GO:0002764 immune response-regulating signaling pathway
GO:0002768 immune response-regulating cell surface receptor signaling pathway
GO:0002819 regulation of adaptive immune response
GO:0002820 negative regulation of adaptive immune response
GO:0002822 regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002823 negative regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002889 regulation of immunoglobulin mediated immune response
GO:0002890 negative regulation of immunoglobulin mediated immune response
GO:0002920 regulation of humoral immune response
GO:0002921 negative regulation of humoral immune response
GO:0002923 regulation of humoral immune response mediated by circulating immunoglobulin
GO:0002924 negative regulation of humoral immune response mediated by circulating immunoglobulin
GO:0006469 negative regulation of protein kinase activity
GO:0006470 protein dephosphorylation
GO:0006816 calcium ion transport
GO:0006874 cellular calcium ion homeostasis
GO:0006875 cellular metal ion homeostasis
GO:0006959 humoral immune response
GO:0007159 leukocyte cell-cell adhesion
GO:0007162 negative regulation of cell adhesion
GO:0007204 positive regulation of cytosolic calcium ion concentration
GO:0007346 regulation of mitotic cell cycle
GO:0007596 blood coagulation
GO:0007599 hemostasis
GO:0010522 regulation of calcium ion transport into cytosol
GO:0010959 regulation of metal ion transport
GO:0014065 phosphatidylinositol 3-kinase signaling
GO:0014066 regulation of phosphatidylinositol 3-kinase signaling
GO:0014068 positive regulation of phosphatidylinositol 3-kinase signaling
GO:0016064 immunoglobulin mediated immune response
GO:0016311 dephosphorylation
GO:0018108 peptidyl-tyrosine phosphorylation
GO:0018212 peptidyl-tyrosine modification
GO:0019724 B cell mediated immunity
GO:0022407 regulation of cell-cell adhesion
GO:0022408 negative regulation of cell-cell adhesion
GO:0022409 positive regulation of cell-cell adhesion
GO:0030098 lymphocyte differentiation
GO:0030099 myeloid cell differentiation
GO:0030168 platelet activation
GO:0030183 B cell differentiation
GO:0030219 megakaryocyte differentiation
GO:0030220 platelet formation
GO:0031294 lymphocyte costimulation
GO:0031295 T cell costimulation
GO:0032844 regulation of homeostatic process
GO:0032845 negative regulation of homeostatic process
GO:0032943 mononuclear cell proliferation
GO:0032944 regulation of mononuclear cell proliferation
GO:0032945 negative regulation of mononuclear cell proliferation
GO:0033277 abortive mitotic cell cycle
GO:0033627 cell adhesion mediated by integrin
GO:0033628 regulation of cell adhesion mediated by integrin
GO:0033630 positive regulation of cell adhesion mediated by integrin
GO:0033673 negative regulation of kinase activity
GO:0034109 homotypic cell-cell adhesion
GO:0034340 response to type I interferon
GO:0034762 regulation of transmembrane transport
GO:0034765 regulation of ion transmembrane transport
GO:0035335 peptidyl-tyrosine dephosphorylation
GO:0035855 megakaryocyte development
GO:0036344 platelet morphogenesis
GO:0042098 T cell proliferation
GO:0042110 T cell activation
GO:0042113 B cell activation
GO:0042129 regulation of T cell proliferation
GO:0042130 negative regulation of T cell proliferation
GO:0042267 natural killer cell mediated cytotoxicity
GO:0042326 negative regulation of phosphorylation
GO:0043405 regulation of MAP kinase activity
GO:0043407 negative regulation of MAP kinase activity
GO:0043409 negative regulation of MAPK cascade
GO:0044770 cell cycle phase transition
GO:0044772 mitotic cell cycle phase transition
GO:0044843 cell cycle G1/S phase transition
GO:0045088 regulation of innate immune response
GO:0045577 regulation of B cell differentiation
GO:0045619 regulation of lymphocyte differentiation
GO:0045785 positive regulation of cell adhesion
GO:0046651 lymphocyte proliferation
GO:0048015 phosphatidylinositol-mediated signaling
GO:0048017 inositol lipid-mediated signaling
GO:0050670 regulation of lymphocyte proliferation
GO:0050672 negative regulation of lymphocyte proliferation
GO:0050730 regulation of peptidyl-tyrosine phosphorylation
GO:0050732 negative regulation of peptidyl-tyrosine phosphorylation
GO:0050777 negative regulation of immune response
GO:0050817 coagulation
GO:0050851 antigen receptor-mediated signaling pathway
GO:0050852 T cell receptor signaling pathway
GO:0050853 B cell receptor signaling pathway
GO:0050854 regulation of antigen receptor-mediated signaling pathway
GO:0050855 regulation of B cell receptor signaling pathway
GO:0050856 regulation of T cell receptor signaling pathway
GO:0050858 negative regulation of antigen receptor-mediated signaling pathway
GO:0050859 negative regulation of B cell receptor signaling pathway
GO:0050860 negative regulation of T cell receptor signaling pathway
GO:0050863 regulation of T cell activation
GO:0050864 regulation of B cell activation
GO:0050865 regulation of cell activation
GO:0050866 negative regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0050868 negative regulation of T cell activation
GO:0050870 positive regulation of T cell activation
GO:0050878 regulation of body fluid levels
GO:0050900 leukocyte migration
GO:0051208 sequestering of calcium ion
GO:0051209 release of sequestered calcium ion into cytosol
GO:0051235 maintenance of location
GO:0051238 sequestering of metal ion
GO:0051249 regulation of lymphocyte activation
GO:0051250 negative regulation of lymphocyte activation
GO:0051251 positive regulation of lymphocyte activation
GO:0051279 regulation of release of sequestered calcium ion into cytosol
GO:0051282 regulation of sequestering of calcium ion
GO:0051283 negative regulation of sequestering of calcium ion
GO:0051348 negative regulation of transferase activity
GO:0051480 regulation of cytosolic calcium ion concentration
GO:0051924 regulation of calcium ion transport
GO:0055074 calcium ion homeostasis
GO:0060337 type I interferon signaling pathway
GO:0060338 regulation of type I interferon-mediated signaling pathway
GO:0060348 bone development
GO:0060401 cytosolic calcium ion transport
GO:0060402 calcium ion transport into cytosol
GO:0060759 regulation of response to cytokine stimulus
GO:0061515 myeloid cell development
GO:0070371 ERK1 and ERK2 cascade
GO:0070372 regulation of ERK1 and ERK2 cascade
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0070509 calcium ion import
GO:0070527 platelet aggregation
GO:0070588 calcium ion transmembrane transport
GO:0070661 leukocyte proliferation
GO:0070663 regulation of leukocyte proliferation
GO:0070664 negative regulation of leukocyte proliferation
GO:0070838 divalent metal ion transport
GO:0071357 cellular response to type I interferon
GO:0071593 lymphocyte aggregation
GO:0071900 regulation of protein serine/threonine kinase activity
GO:0071901 negative regulation of protein serine/threonine kinase activity
GO:0072503 cellular divalent inorganic cation homeostasis
GO:0072507 divalent inorganic cation homeostasis
GO:0072511 divalent inorganic cation transport
GO:0090279 regulation of calcium ion import
GO:0097553 calcium ion transmembrane import into cytosol
GO:0098751 bone cell development
GO:1901987 regulation of cell cycle phase transition
GO:1901990 regulation of mitotic cell cycle phase transition
GO:1902105 regulation of leukocyte differentiation
GO:1902532 negative regulation of intracellular signal transduction
GO:1902656 calcium ion import into cytosol
GO:1902806 regulation of cell cycle G1/S phase transition
GO:1903037 regulation of leukocyte cell-cell adhesion
GO:1903038 negative regulation of leukocyte cell-cell adhesion
GO:1903039 positive regulation of leukocyte cell-cell adhesion
GO:1903169 regulation of calcium ion transmembrane transport
GO:1903706 regulation of hemopoiesis
GO:1904062 regulation of cation transmembrane transport
GO:2000021 regulation of ion homeostasis
GO:2000045 regulation of G1/S transition of mitotic cell cycle
Molecular Function GO:0001784 phosphotyrosine binding
GO:0004721 phosphoprotein phosphatase activity
GO:0004725 protein tyrosine phosphatase activity
GO:0005001 transmembrane receptor protein tyrosine phosphatase activity
GO:0016791 phosphatase activity
GO:0017124 SH3 domain binding
GO:0019198 transmembrane receptor protein phosphatase activity
GO:0042169 SH2 domain binding
GO:0042578 phosphoric ester hydrolase activity
GO:0045309 protein phosphorylated amino acid binding
GO:0050839 cell adhesion molecule binding
GO:0051219 phosphoprotein binding
Cellular Component GO:0042101 T cell receptor complex
GO:0042105 alpha-beta T cell receptor complex
GO:0043235 receptor complex
GO:0098802 plasma membrane receptor complex
> KEGG and Reactome Pathway
 
KEGG hsa04520 Adherens junction
hsa04630 Jak-STAT signaling pathway
hsa04650 Natural killer cell mediated cytotoxicity
hsa04660 T cell receptor signaling pathway
hsa04662 B cell receptor signaling pathway
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-983695: Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
R-HSA-5690714: CD22 mediated BCR regulation
R-HSA-202733: Cell surface interactions at the vascular wall
R-HSA-1500931: Cell-Cell communication
R-HSA-388841: Costimulation by the CD28 family
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-114604: GPVI-mediated activation cascade
R-HSA-982772: Growth hormone receptor signaling
R-HSA-109582: Hemostasis
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-913531: Interferon Signaling
R-HSA-909733: Interferon alpha/beta signaling
R-HSA-877300: Interferon gamma signaling
R-HSA-912526: Interleukin receptor SHC signaling
R-HSA-451927: Interleukin-2 signaling
R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling
R-HSA-6798695: Neutrophil degranulation
R-HSA-389948: PD-1 signaling
R-HSA-210990: PECAM1 interactions
R-HSA-76002: Platelet activation, signaling and aggregation
R-HSA-418346: Platelet homeostasis
R-HSA-432142: Platelet sensitization by LDL
R-HSA-912694: Regulation of IFNA signaling
R-HSA-877312: Regulation of IFNG signaling
R-HSA-1433559: Regulation of KIT signaling
R-HSA-162582: Signal Transduction
R-HSA-391160: Signal regulatory protein (SIRP) family interactions
R-HSA-449147: Signaling by Interleukins
R-HSA-1433557: Signaling by SCF-KIT
R-HSA-983705: Signaling by the B Cell Receptor (BCR)
Summary
SymbolPTPN6
Nameprotein tyrosine phosphatase, non-receptor type 6
Aliases HCPH; PTP-1C; SHP-1; HPTP1C; SH-PTP1; SHP-1L; hematopoietic cell phosphatase; hematopoietic cell protein-tyr ......
Chromosomal Location12p13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PTPN6 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between PTPN6 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
27430370Lung CarcinomaInhibit immunity (T cell function)Using this model, we demonstrate that the absence of SHP-1 augments the ability of adoptively transferred CD8(+) T cells to control tumor growth. Despite this caveat, our findings support the development of SHP-1 inhibition strategies in human T cells to complement adoptive transfer therapies in the clinic.
22798667LeukemiaInhibit immunityWe found that the abrogation of Src homology region 2 domain-containing phosphatase-1 (SHP-1) in tumor-reactive CD8(+) T cells improves the therapeutic outcome of adoptive immunotherapy in a mouse model of disseminated leukemia, with benefit observed in therapy employing transfer of CD8(+) T cells alone or in the context of also providing supplemental IL-2. Following transfer in vivo, the SHP-1(-/-) effector T cells exhibited enhanced short-term accumulation, followed by greater contraction, and they ultimately formed similar numbers of long-lived, functional memory cells. The increased therapeutic effectiveness of SHP-1(-/-) effector cells was also observed in recipients that expressed the tumor Ag as a self-antigen in the liver, without evidence of inducing autoimmune toxicity. SHP-1(-/-) effector CD8(+) T cells expressed higher levels of eomesodermin, which correlated with enhanced lysis of tumor cells.
Summary
SymbolPTPN6
Nameprotein tyrosine phosphatase, non-receptor type 6
Aliases HCPH; PTP-1C; SHP-1; HPTP1C; SH-PTP1; SHP-1L; hematopoietic cell phosphatase; hematopoietic cell protein-tyr ......
Chromosomal Location12p13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PTPN6 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolPTPN6
Nameprotein tyrosine phosphatase, non-receptor type 6
Aliases HCPH; PTP-1C; SHP-1; HPTP1C; SH-PTP1; SHP-1L; hematopoietic cell phosphatase; hematopoietic cell protein-tyr ......
Chromosomal Location12p13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PTPN6 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1280.809
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.1960.913
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0730.96
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.4410.288
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.3310.858
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.590.819
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.540.305
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.7820.577
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2540.872
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.750.696
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.6440.828
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0250.736
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PTPN6 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277304.1-4.10.561
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275905.1-5.10.549
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPTPN6
Nameprotein tyrosine phosphatase, non-receptor type 6
Aliases HCPH; PTP-1C; SHP-1; HPTP1C; SH-PTP1; SHP-1L; hematopoietic cell phosphatase; hematopoietic cell protein-tyr ......
Chromosomal Location12p13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PTPN6. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPTPN6
Nameprotein tyrosine phosphatase, non-receptor type 6
Aliases HCPH; PTP-1C; SHP-1; HPTP1C; SH-PTP1; SHP-1L; hematopoietic cell phosphatase; hematopoietic cell protein-tyr ......
Chromosomal Location12p13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PTPN6. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PTPN6.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPTPN6
Nameprotein tyrosine phosphatase, non-receptor type 6
Aliases HCPH; PTP-1C; SHP-1; HPTP1C; SH-PTP1; SHP-1L; hematopoietic cell phosphatase; hematopoietic cell protein-tyr ......
Chromosomal Location12p13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PTPN6. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPTPN6
Nameprotein tyrosine phosphatase, non-receptor type 6
Aliases HCPH; PTP-1C; SHP-1; HPTP1C; SH-PTP1; SHP-1L; hematopoietic cell phosphatase; hematopoietic cell protein-tyr ......
Chromosomal Location12p13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PTPN6 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPTPN6
Nameprotein tyrosine phosphatase, non-receptor type 6
Aliases HCPH; PTP-1C; SHP-1; HPTP1C; SH-PTP1; SHP-1L; hematopoietic cell phosphatase; hematopoietic cell protein-tyr ......
Chromosomal Location12p13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PTPN6 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPTPN6
Nameprotein tyrosine phosphatase, non-receptor type 6
Aliases HCPH; PTP-1C; SHP-1; HPTP1C; SH-PTP1; SHP-1L; hematopoietic cell phosphatase; hematopoietic cell protein-tyr ......
Chromosomal Location12p13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PTPN6 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.